Polyrizon Ltd. (Nasdaq: PLRZ), an Israel-based development-stage biotech company, announced it received central institutional review board approval to begin its first human clinical trial for NASARIX, a nasal spray designed to block airborne allergens.

The approval was granted by the BRANY Institutional Review Board on June 18, 2026, and remains valid through June 17, 2027. It covers the study protocol, patient consent forms, and trial materials, confirming they satisfy applicable ethical and participant protection requirements.

The approved study, titled "Evaluation of the Efficacy, Safety, and Tolerability of NASARIX Allergy Blocker Compared to Saline Spray in Patients with Seasonal Allergic Rhinitis," will compare NASARIX against a saline spray control to assess symptom relief and patient outcomes in those with seasonal allergic rhinitis.

The BRANY approval applies to the master protocol and supporting documentation. Individual clinical sites are required to obtain separate site-specific approvals before initiating study activities or enrolling participants.

"We are pleased to have received approval for the study master file and look forward to progressing toward site activation and patient enrollment following completion of site-specific IRB approvals," said Tomer Izraeli, CEO of Polyrizon.

NASARIX is described by the company as a non-drug approach intended to create a protective barrier within the nasal cavity to prevent contact between inhaled allergens and the nasal mucosa.